{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.311","upperLimit":"0.759","value":"0.486"}]}],"title":"PFS at year 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.108","upperLimit":"0.615","value":"0.315"}]}],"title":"PFS at year 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"l be progression-free survival (PFS)\n\n1 and 3 years after start of treatment as well as the duration of response from start of therapy, defined per Cheson criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Reported at 1 and 3 years after the start of treatment","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"PFS Probability"}